Industry News
Biotechnology Industry News

Hemab raises $55M to target multiple rare bleeding indications
Hemab raises $55M to target multiple rare bleeding indications ntaylor Wed, 07/21/2021 - 08:43
Vedanta raises $68M, reveals setback to Bristol Myers alliance
Vedanta raises $68M, reveals setback to Bristol Myers alliance ntaylor Wed, 07/21/2021 - 08:16
Coave raises $25M ahead of pivotal retinal gene therapy trial
Coave raises $25M ahead of pivotal retinal gene therapy trial ntaylor Wed, 07/21/2021 - 07:26
Novartis ditches midstage dry eye drug, gets New Year’s PDUFA data for troubled Leqvio
Novartis ditches midstage dry eye drug, gets New Year’s PDUFA data for troubled Leqvio badams Wed, 07/21/2021 - 04:41
Bayer’s drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice
Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice aliu Wed, 07/21/2021 - 04:40
Rivus’ fat-trimming therapy nabs $35M to harness our own biology against a host of diseases
Rivus’ fat-trimming therapy nabs $35M to harness our own biology against a host of diseases badams Tue, 07/20/2021 - 09:10
In an unusual crossover, Gilead hires Arcus CMO Grossman, putting him in charge of cancer pact with his former biotech
In an unusual crossover, Gilead hires Arcus CMO Grossman, putting him in charge of cancer pact with his former biotech ntaylor Tue, 07/20/2021 - 07:54
Panakès moves into biotech investing with new €150M fund
Panakès moves into biotech investing with new €150M fund ntaylor Tue, 07/20/2021 - 07:28
Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug
Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug badams Tue, 07/20/2021 - 06:48
Surprise genetic discovery in macular degeneration points to new treatment strategy
Surprise genetic discovery in macular degeneration points to new treatment strategy arlene.weintraub Mon, 07/19/2021 - 08:57
Rome, backed by Arch and GV, hires science leaders to hit targets in “junk DNA”
Rome, backed by Arch and GV, hires science leaders to hit targets in “junk DNA” ntaylor Mon, 07/19/2021 - 08:10
Adagio seeks IPO to bring COVID-19 antibody to market in 2022
Adagio seeks IPO to bring COVID-19 antibody to market in 2022 ntaylor Mon, 07/19/2021 - 07:24
Troubled Cytokinetics’ stock soars as gets much needed phase 2 heart drug trial win, plans late-stage effort by year’s end
Troubled Cytokinetics' stock soars as gets much needed phase 2 heart drug trial win, plans late-stage effort by year’s end badams Mon, 07/19/2021 - 05:18
Regeneron plans $1.8B upgrade at Tarrytown campus, where it aims to add 1,000 new staffers over 5 years
Regeneron plans $1.8B upgrade at Tarrytown campus, where it aims to add 1,000 new staffers over 5 years fkansteiner Fri, 07/16/2021 - 10:30
Polyphor sharpens ax on staff, shutters failed breast cancer test
Polyphor sharpens ax on staff, shutters failed breast cancer test ntaylor Fri, 07/16/2021 - 06:30
GSK sells off part of its U.K. R&D site to rake in $554M and boost biotech ops
GSK sells off part of its U.K. R&D site to rake in $554M and boost biotech ops ntaylor Fri, 07/16/2021 - 05:10
2 pathways that prepare and kill melanoma cells could inspire novel anti-cancer drugs
2 pathways that prepare and kill melanoma cells could inspire novel anti-cancer drugs klahucik Thu, 07/15/2021 - 17:38
Gene therapy delivered to the brain shows promise in children with rare neurodegenerative disease
Gene therapy delivered to the brain shows promise in children with rare neurodegenerative disease arlene.weintraub Thu, 07/15/2021 - 09:39
Galapagos avoids ‘complete whiff’ as key anti-inflammatory drug fails to beat placebo in midphase trials
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials ntaylor Thu, 07/15/2021 - 08:05
A tale of 2 (bio) cities: Moderna tops $100B valuation, matching GlaxoSmithKline
A tale of 2 (bio) cities: Moderna tops $100B valuation, matching GlaxoSmithKline badams Thu, 07/15/2021 - 05:00

